Cord Blood America announced today that it has signed a consulting agreement with Midtown Partners & Co., LLC to find ways to unlock value for its subsidiaries.
Matthew Schissler, Cord Blood America Chairman and CEO, stated, “Management sees this opportunity as a significant step forward in Cord Blood America’s overall business plan. Management has worked diligently to line up this milestone opportunity, which could entirely fund the parent Company’s future growth.”
The Senior Vice President at Midtown Parners commented on Cord Blood as being valuable, but doesn’t have the same attention other companies have in the public markets. He commented, “Cord Blood America has some of the best financial numbers in the sector, yet has not achieved the name recognition deserved in the stem cell arena. We want to improve the street perception of the company and do it quickly by identifying the best strategic alternatives for the company and its subsidiaries.”
The capital required to fund the transaction will be funded entirely from finances made available through the new transaction. It is the company’s mission to continue with accretive acquisitions, strategic organic growth and to improve the balance sheet.
In closing, Mr. Schissler stated, “This process should allow the company to realize its full potential.”
Let us hear your thoughts below: